Skip to main content
. 2019 Aug 6;12:155–166. doi: 10.2147/PGPM.S210770

Figure 1.

Figure 1

The prevalence of metabolic abnormality in patients receiving risperidone or clozapine. Metabolic syndrome and its major components are defined using the NCEP ATP III criteria modified for Asian population.27 *p-value<0.05.